A Phase II study of pazopanib in metastatic merkel cell carcinoma

Trial Profile

A Phase II study of pazopanib in metastatic merkel cell carcinoma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Merkel cell carcinoma
  • Focus Therapeutic Use
  • Acronyms UKMCC01
  • Most Recent Events

    • 07 Jun 2016 Status changed from recruiting to discontinued as the primary endpoint of was met and the accrual was very slow, according to the Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 07 Jun 2016 Primary endpoint (Clinical response rate measured by RECIST) has been met, according to the Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top